KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical
Mar 09, 2017 12:31 pm UTC| Business
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
K2M Group Holdings, Inc. to Participate in Two Upcoming Investor Conferences in March
Mar 09, 2017 12:31 pm UTC| Business
LEESBURG, Va., March 09, 2017 -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body...
K2M Group Holdings, Inc. to Participate in Two Upcoming Investor Conferences in March
Mar 09, 2017 12:31 pm UTC| Business
LEESBURG, Va., March 09, 2017 -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body...
Peak Resorts Reports Results for Third Quarter FY2017
Mar 09, 2017 12:31 pm UTC| Business
WILDWOOD, Mo., March 09, 2017 -- Peak Resorts, Inc. (NASDAQ:SKIS), a leading owner and operator of high-quality, individually branded ski resorts in the U.S., today reported results for its fiscal third quarter and nine...
Peak Resorts Reports Results for Third Quarter FY2017
Mar 09, 2017 12:31 pm UTC| Business
WILDWOOD, Mo., March 09, 2017 -- Peak Resorts, Inc. (NASDAQ:SKIS), a leading owner and operator of high-quality, individually branded ski resorts in the U.S., today reported results for its fiscal third quarter and nine...
Mar 09, 2017 12:31 pm UTC| Business
Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent...
Mar 09, 2017 12:31 pm UTC| Business
Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent...